These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 36658048)

  • 1. Multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD) following COVID-19 vaccines: A systematic review.
    Mirmosayyeb O; Ghaffary EM; Vaheb S; Pourkazemi R; Shaygannejad V
    Rev Neurol (Paris); 2023 Apr; 179(4):265-281. PubMed ID: 36658048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Watch out for neuromyelitis optica spectrum disorder onset or clinical relapse after COVID-19 vaccination: What neurologists need to know?
    Paybast S; Emami A; Baghalha F; Naser Moghadasi A
    Mult Scler Relat Disord; 2022 Sep; 65():103960. PubMed ID: 35763914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Severe disease exacerbation after mRNA COVID-19 vaccination unmasks suspected multiple sclerosis as neuromyelitis optica spectrum disorder: a case report.
    Lohmann L; Glaser F; Möddel G; Lünemann JD; Wiendl H; Klotz L
    BMC Neurol; 2022 May; 22(1):185. PubMed ID: 35585528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Post COVID-19 infection neuromyelitis optica spectrum disorder (NMOSD): A case report-based systematic review.
    Mirmosayyeb O; Ghaffary EM; Bagherieh S; Barzegar M; Dehghan MS; Shaygannejad V
    Mult Scler Relat Disord; 2022 Apr; 60():103697. PubMed ID: 35306242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relapses after SARS-CoV-2 vaccination in patients with neuromyelitis optica spectrum disorder and multiple sclerosis.
    Kong L; Wang X; Chen H; Shi Z; Lang Y; Zhang Y; Zhou H
    Mult Scler Relat Disord; 2022 Dec; 68():104167. PubMed ID: 36170773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparing the consequences of COVID-19 vaccination between central nervous system (CNS) demyelinating diseases and other neurological disorders.
    Yazdan Panah M; Vaheb S; Mokary Y; Afshari-Safavi A; Shaygannejad A; Ebrahimi N; Shaygannejad V; Mirmosayyeb O
    Vaccine; 2024 Oct; 42(23):126061. PubMed ID: 38886142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple sclerosis, neuromyelitis optica spectrum disorder and COVID-19: A pandemic year in Czechia.
    Stastna D; Menkyova I; Drahota J; Mazouchova A; Adamkova J; Ampapa R; Grunermelova M; Peterka M; Recmanova E; Rockova P; Rous M; Stetkarova I; Valis M; Vachova M; Woznicova I; Horakova D
    Mult Scler Relat Disord; 2021 Sep; 54():103104. PubMed ID: 34216998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fulminant neuromyelitis optica spectrum disorder (NMOSD) following COVID-19 vaccination: A need for reconsideration?
    Motahharynia A; Naghavi S; Shaygannejad V; Adibi I
    Mult Scler Relat Disord; 2022 Oct; 66():104035. PubMed ID: 35858498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of SARS-CoV2 vaccination and COVID-19 short-term outcome in pediatric acquired demyelinating disorders of central nervous system: A single center experience.
    Monte G; Papetti L; Ferilli MAN; Ursitti F; Moavero R; Sforza G; Panella E; Tarantino S; Checchi MP; Vigevano F; Palma P; Valeriani M
    Front Immunol; 2023; 14():1106472. PubMed ID: 36761740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New onset or relapsing neuromyelitis optica temporally associated with SARS-CoV-2 infection and COVID-19 vaccination: a systematic review.
    Harel T; Gorman EF; Wallin MT
    Front Neurol; 2023; 14():1099758. PubMed ID: 37426444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aquaporin-4 IgG neuromyelitis optica spectrum disorder onset after Covid-19 vaccination: Systematic review.
    Harahsheh E; Callister M; Hasan S; Gritsch D; Valencia-Sanchez C
    J Neuroimmunol; 2022 Dec; 373():577994. PubMed ID: 36332464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current and emerging therapeutics for neuromyelitis optica spectrum disorder: Relevance to the COVID-19 pandemic.
    Abboud H; Zheng C; Kar I; Chen CK; Sau C; Serra A
    Mult Scler Relat Disord; 2020 Sep; 44():102249. PubMed ID: 32526698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. To be or not to be vaccinated: The risk of MS or NMOSD relapse after COVID-19 vaccination and infection.
    Stastna D; Menkyova I; Drahota J; Hrnciarova T; Kubala Havrdova E; Vachova M; Andelova M; Kleinova P; Kovarova I; Krasulova E; Preiningerova JL; Novakova I; Novotna K; Novotna M; Nytrova P; Pavlickova J; Srpova B; Storey K; Ticha V; Tyblova M; Uher T; Vodehnalova K; Horakova D
    Mult Scler Relat Disord; 2022 Sep; 65():104014. PubMed ID: 35803085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COVID-19 infection after two doses of SARS-CoV-2 mRNA vaccine in multiple sclerosis, AQP4-antibody NMOSD and MOGAD.
    Yeo T; Quek AML; Yong KP; Tye JSN; Ratnagopal P; Soon DTL; Tan K
    Mult Scler Relat Disord; 2022 Sep; 65():104003. PubMed ID: 35803084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Seropositive Neuromyelitis Optica in a Case of Undiagnosed Ankylosing Spondylitis: A Neuro-Rheumatological Conundrum.
    Ghosh Md R; Roy D; León-Ruiz M; Das S; Dubey S; Benito-León J
    Qatar Med J; 2022; 2022(3):29. PubMed ID: 35864917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of mental health, knowledge, and attitude of patients with multiple sclerosis and neuromyelitis optica spectrum disorder in response to 2019 novel coronavirus.
    Shaygannejad V; Afshari-Safavi A; Hatef B
    Neurol Sci; 2021 Jul; 42(7):2891-2901. PubMed ID: 33219424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CNS demyelinating disease following inactivated or viral vector SARS-CoV-2 vaccines: A case series.
    Ebrahimi N; Mazdak M; Shaygannejad V; Mirmosayyeb O
    Vaccine; 2023 Jan; 41(5):1003-1008. PubMed ID: 36635139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. COVID-19 in multiple sclerosis and neuromyelitis optica spectrum disorder patients in Latin America: COVID-19 in MS and NMOSD patients in LATAM.
    Alonso R; Silva B; Garcea O; Diaz PEC; Dos Passos GR; Navarro DAR; Valle LAG; Salinas LCR; Negrotto L; Luetic G; Tkachuk VA; Míguez J; de Bedoya FHD; Goiry LG; Sánchez NER; Burgos M; Steinberg J; Balbuena ME; Alvarez PM; López PA; Ysrraelit MC; León RA; Cohen AB; Gracia F; Molina O; Casas M; Deri NH; Pappolla A; Patrucco L; Cristiano E; Tavolini D; Nadur D; Granda AMT; Weiser R; Cassará FP; Sinay V; Rodríguez CC; Lazaro LG; Menichini ML; Piedrabuena R; Escobar GO; Carrá A; Chertcoff A; Pujols BS; Vrech C; Tarulla A; Carvajal R; Mainella C; Becker J; Peeters LM; Walton C; Serena MA; Nuñez S; Rojas JI
    Mult Scler Relat Disord; 2021 Jun; 51():102886. PubMed ID: 33744758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CNS inflammatory demyelinating events after COVID-19 vaccines: A case series and systematic review.
    Rinaldi V; Bellucci G; Buscarinu MC; Reniè R; Marrone A; Nasello M; Zancan V; Nistri R; Palumbo R; Salerno A; Salvetti M; Ristori G
    Front Neurol; 2022; 13():1018785. PubMed ID: 36530641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential brainstem atrophy patterns in multiple sclerosis and neuromyelitis optica spectrum disorders.
    Lee CY; Mak HK; Chiu PW; Chang HC; Barkhof F; Chan KH
    J Magn Reson Imaging; 2018 Jun; 47(6):1601-1609. PubMed ID: 28990252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.